Educational content only. Not medical advice. Consult a qualified physician.
Dihexa peptide
CognitiveResearch-only. Not FDA-approved. All published data is preclinical (animal and in vitro). No human clinical trials have been conducted.

Dihexa

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a synthetic peptide derived from angiotensin IV. Developed at Washington State University by Dr. Joseph Harding, it was found to be up to 10 million times more potent than BDNF at promoting hepatocyte growth factor (HGF) signaling. Research has focused on its potential to drive synaptogenesis and cognitive enhancement.
Reported Benefits

Potential Benefits

  • Preclinical studies suggest potent promotion of new synapse formation
  • Animal models indicate potential cognitive enhancement in both healthy and impaired subjects
  • May cross the blood-brain barrier when taken orally based on animal data
  • Research suggests potential for neurodegenerative disease applications
  • Acts through the HGF/c-Met receptor system, a pathway involved in neural development
Research Dosing

Recommended Starting Dose

10-20 mg orally or 5-10 mg subcutaneously (highly experimental; no established human dose)

Based on published research protocols. Not a prescription.

Dosing Protocol

No established human dosing protocol. Anecdotal reports describe oral doses of 10-20 mg daily or sublingual administration. Some use subcutaneous injection. Given the lack of human safety data, extreme caution is warranted. This is among the most experimental compounds on this list.

DOSING INFORMATION DISCLAIMER: Any dosing information, protocols, or ranges discussed on this site are drawn from published research studies and clinical literature. They are presented for educational reference only and must not be used as self-medication guidance.

Research Timeline

Expected Timeline

Phase 1

Anecdotal reports vary widely. Some users report cognitive changes within days, though this has not been validated in any clinical study.

Regulatory

Research Status

Research-only. Not FDA-approved. All published data is preclinical (animal and in vitro). No human clinical trials have been conducted.

The regulatory status of peptides can change at any time. Verify current FDA classification and legal status in your jurisdiction before seeking medical consultation about this compound.

Safety Profile

Potential Side Effects

  • No published human safety data
  • Potent biological activity raises concerns about unpredictable effects
  • Theoretical risk of promoting unwanted cell growth (HGF/c-Met pathway is implicated in some cancers)
  • Long-term effects in any species are not well-characterized
  • Unregulated compound with significant quality control concerns
Related Research

More in Cognitive

Medical Disclaimer

EDUCATIONAL CONTENT ONLY: The peptide information presented on this page is compiled from published scientific literature, peer-reviewed research, and publicly available clinical data. It is provided strictly for educational purposes and does not constitute medical advice, an endorsement of any specific peptide, or a recommendation for treatment. Many peptides discussed on this site have not received FDA approval for human therapeutic use. Some may be under active regulatory review or subject to restrictions on compounding under FDA Section 503A and 503B frameworks. The regulatory status of individual peptides can change at any time. Readers should verify the current legal status of any peptide in their jurisdiction before pursuing further information or consultation. If you are considering peptide therapy, seek guidance from a licensed physician or healthcare provider who specializes in peptide-based treatments and operates within applicable federal and state regulations.